Erasca prices upsized $550M stock offering to fund cancer pipeline
What's the deal? Erasca, a clinical-stage precision oncology company listed on the Nasdaq, has priced an upsized public offering of 31,428,572 shares of common stock at $17.50 each. The company expects gross proceeds of roughly $550 million, before underwriting discounts and other expenses. The offering is due to close on July 15, 2026.
What's the endgame? Erasca is focused on therapies for RAS/MAPK pathway-driven cancers. It plans to use the net proceeds, together with existing cash, to fund research and development of its product candidates, other development programs, and general corporate purposes.
Why now? The raise comes as a follow-on to an earlier listing, giving the company additional runway to advance its pipeline. It has also granted underwriters a 30-day option to buy up to 4,714,285 more shares at the offering price.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are acting as joint book-running managers for the offering.
The signal: At $550 million, this ranks in the 98th percentile of all-time post-IPO equity rounds by US health companies. That scale signals continued investor appetite for late-stage oncology plays, even at the capital-intensive clinical stage.
Read more: globenewswire.com
Image credit: National Institutes of Health (NIH)
